BMY - Bristol-Myers Squibb Company
| Previous Close | 57.83 |
| Open | 57.93 |
| Bid | 58.27 x 800 |
| Ask | 58.28 x 800 |
| Day's Range | 57.68 - 58.63 |
| 52 Week Range | 49.96 - 70.05 |
| Volume | 1,496,381 |
| Avg. Volume | 5,762,872 |
| Market Cap | 95.547B |
| Beta (3Y Monthly) | 1.16 |
| PE Ratio (TTM) | 260.22 |
| EPS (TTM) | 0.22 |
| Earnings Date | Oct 25, 2018 |
| Forward Dividend & Yield | 1.60 (2.78%) |
| Ex-Dividend Date | 2018-10-04 |
| 1y Target Est | 61.59 |
- Yahoo Finance Video•22 hours ago
Government wants drug companies to disclose prices on TV ads
New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.
- Business Wire•5 hours ago
Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody as a biomarker of poor prognosis in pati
Market Realist•21 hours agoHow Nektar Therapeutics Is Positioned In October
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
American City Business Journals•2 days agoHealth Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
- Zacks•2 days ago
Bristol-Myers Reports Disappointing Data From SCLC Study
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
- Zacks•2 days ago
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
- Market Realist•2 days ago
Novartis: What to Expect from Q3 Earnings on October 18
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
- Zacks•5 days ago
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
- Zacks•5 days ago
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
- Zacks•5 days ago
4 Top Stocks to Buy for Superb Earnings Growth
We select four stocks that have striking earnings growth and positive estimate revisions.
- Reuters•5 days ago
Bristol-Myers' Opdivo fails to meet lung cancer study goal
Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy. The drug failed to extend overall survival in patients suffering from small cell lung cancer, an aggressive form of the disease, when compared to patients already on chemotherapy. Opdivo has already been approved to treat several forms of cancer, including skin and lung cancer.
- MarketWatch•5 days ago
Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains," said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. "We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer." Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 has gained 2.1%.
- Business Wire•5 days ago
Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer
Bristol-Myers Squibb Company today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin , in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
Market Realist•6 days agoWhat to Expect from Johnson & Johnson’s Q3 2018 Earnings
Johnson & Johnson (JNJ) plans to report its third-quarter earnings on October 16. Wall Street analysts expect JNJ to register adjusted EPS of $2.03 in the third quarter, representing YoY (year-over-year) growth of ~6.7%. In comparison, the company reported second-quarter adjusted EPS of $2.10.
